Twist Bioscience (TWST) Liabilities and Shareholders Equity (2018 - 2026)

Twist Bioscience (TWST) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $676.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.53% year-over-year to $676.2 million; the TTM figure through Mar 2026 stood at $2.6 billion (up 5.83% YoY), while the FY2025 annual figure was $641.9 million, up 4.48% from the prior year.
• Liabilities and Shareholders Equity grew to $676.2 million in Q1 2026 per TWST's latest filing, from $638.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.0 billion in Q1 2022 and bottomed at $595.6 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $753.3 million across 5 years, with a median of $702.8 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 50.84% — and 2024, when it retreated 21.25%.
• Twist Bioscience's Liabilities and Shareholders Equity stood at $910.0 million in 2022, then dropped by 19.47% to $732.8 million in 2023, then retreated by 16.95% to $608.6 million in 2024, then grew by 4.85% to $638.1 million in 2025, then advanced by 5.98% to $676.2 million in 2026.
• Business Quant data shows TWST's Liabilities and Shareholders Equity at $676.2 million in Q1 2026, $638.1 million in Q4 2025, and $641.9 million in Q3 2025.